These findings reveal a novel mechanism that regulates AA metabolism in osteosarcoma and suggests a promising treatment strategy of targeting FUBP1 and AA metabolism to enhance the lobaplatin response during osteosarcoma chemoresistance. This evidence concerns the gene FUBP1 and osteosarcoma.